Clive Mean­well gives way to new CEO as ac­tivist in­vestor Alex Den­ner shakes up The Med­i­cines Com­pa­ny

Alex Den­ner has made his first pub­lic move at The Med­i­cines Com­pa­ny since con­sol­i­dat­ing pow­er on the board — and it’s a big one.

Clive Mean­well pass­ing the CEO role and his board seat to Mer­ck vet Mark Tim­ney, leav­ing a po­si­tion he’s oc­cu­pied for the bet­ter part of the com­pa­ny’s 22-year his­to­ry.

He’s not out en­tire­ly. In the new­ly-cre­at­ed role of chief in­no­va­tion of­fi­cer, he is tasked with sup­port­ing the on­go­ing de­vel­op­ment of in­clisir­an — the biotech’s ex­per­i­men­tal LDL-low­er­ing RNAi ther­a­py in-li­censed from Al­ny­lam.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.